Table 3:
Summary of available results from CD5 and CD7 CAR-T cell studies
| Study | Total No. Patients (No. TCL Patients) | Median Age (Range), y | Target (CAR Type) | Subtypes of TCL | LDC | Costimulatory Endodomain (Vector) | Range of CAR-T Cells Doses | Responses % (n) | CRS & ICANS % (n) | |
|---|---|---|---|---|---|---|---|---|---|---|
| CD5 | ||||||||||
| Rouce et al.42 | 2021 | 99 | 63 (27–71) | CD5 (Autologous) | PTCL (n = 4) AITL (n = 2) CTCL (n = 2) ATLL (n = 1) |
Flu + Cy | CD28 (γ-retrovirus) | 0.1–1.0 × 108 cells/m2 | ORR 44%4
CR 33%3,a PR 11%1 |
CRS, all grades: 44%4
CRS, grade ≥3: 0% ICANS, all grades: 11%1 ICANS, grade ≥3: 0% |
| Pan et al.43 | 2022 | 5 (0) | NR | CD5 (donor-derived) | N.A | NR | 4–1BB (Lentivirus) | 0.5–1.0 × 106 cells/kg | ORR 100%5
CR 100%5 |
CRS 80%4
CRS, grade ≥3: 0% ICANS, all grades: NR ICANS, grade ≥3: NR |
| CD7 | ||||||||||
| Zhang et al.46 | 2023 | 105 | 32 (16–69) | CD7 (autologous or donor-derived) | AITL (n = 1) CTCL (n = 1) TLBL (n = 3) |
Flu + Cy | 4–1BB (Lentivirus) | 1.0–2.0 × 106 cells/kg | ORR 70% (7/10)b | CRS, all grades: 80%8
CRS, grade ≥3: 10%1 ICANS, all grades: 0% ICANS, grade ≥3: 0% |
| Hu et al,47 | 2022 | 124 | 34 (8–66) | CD7 (donor-derived) | PTCL, NOS (n = 1) EBV + NK/TCL (n = 1) TLBL (n = 2) |
Flu + Cy + Etop | 4–1BB (Lentivirus) | 2 × 107 cells/kg | ORR 75% (9/12) CR 58% (7/12)c PR 17% (2/12) |
CRS, all grades: 83%10
CRS, grade ≥3: 0% ICANS, all grades: 0% ICANS, grade ≥3: 0% |
| Lu et al,48 | 2022 | 206 | 223–47 | CD7 (autologous or donor-derived) | TLBL (n = 6) | Flu + Cy | 4–1BB (Lentivirus) | 0.5–2.0 × 106 cells/kg | ORR 95% (19/20) CR 80% (16/20) PR 10% (2/20) |
CRS, all grades: 95%19
CRS, grade ≥3: 5%1 ICANS, all grades: 10%2 ICANS, grade ≥3: 0% |
| Pan et al,49 | 2022 | 20 (0) | 112–43 | CD7 (donor-derived) | N.A | Flu + Cy | 4–1BB (Lentivirus) | 0.5–1.0 × 106 cells/kg | ORR 95% (19/20) CR 90% (18/20) PR 5% (1/20) |
CRS, all grades: 100%20
CRS, grade ≥3: 10%2 ICANS all grades: 15%3 ICANS, grade ≥3: 0% |
Abbreviations: AITL, angioimmunoblastic T-cell lymphoma; ATLL, adult T-cell leukemia/lymphoma; CR, complete response; CRS, cytokine release syndrome; CTCL, cutaneous T-cell lymphoma; Cy-flu, cyclophosphamide+ fludarabine; EBV, Epstein-Barr virus; EBV+ NK/TCL, EBV-associated NK/T-cell lymphomap; Etop, etoposide; ICANS, immune effector cell–associated neurotoxicity syndrome; LDC, lymphodepleting chemotherapy; NOS, not otherwise specified; NR, not reported; ORR, overall response rate; PR, partial response; PTCL, peripheral T-cell lymphoma; TCL, T-cell lymphoma.
Two AITL and one PTCL achieved CR. ATLL patient achieved PR; result details were provided courtesy of Dr. LaQuisa Hill.
Details on CR and PR rates were not clear. CTCL patient achieved PR. No individual data were reported about the AITL patient.
One PTCL, NOS patient achieved CR, and one EBV+ NK/TCL achieved PR.